The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
Now in Phase II clinical trials, a new, oral HCV protease inhibitor, SCH 503034, may defeat the virus in interferon non-responders. Find out how well the drug is tolerated and how it is able to reduce the viral load of non-responders with genotype 1.
Continue reading »Spring 2007 brought a wave of health-related news professing a cure for Hepatitis C. While this publicity inspired hope in millions of people living with chronic HCV, it also sparked frustration and confusion. Learn more about the recent announcement that implied a cure for this disease, as well as what the details of the newsworthy study actually mean for you and your loved ones.
Continue reading »Human Genome Sciences and Novartis are working together to improve Hepatitis C treatment with the long acting version of interferon, Albuferon. The ongoing, Phase II study demonstrated that Albuferon has a success rate equal to, or better than pegylated interferon. Learn why Albuferon becoming the preferred treatment over pegylated interferon is good news for Hepatitis C patients.
Continue reading »Achillion recently revealed progress in preventing Hepatitis C viral replication. Although discontinued due to its strain on the kidneys, clinical trials with ACH-806 demonstrated potent HCV anti-viral activity. Find out how those results may shape the development of the next generation of drugs that carry the hope of finding a more effective HCV treatment.
Continue reading »Since interferon medication is quickly broken down by a person's circulatory and digestive systems, its potency is typically short-lived. By resisting rapid breakdown, Nautilus Biotech's newly engineered interferon-alpha drug, Belerofon, shows promise in increased effectiveness against Hepatitis C. Now in a Phase I study, we will soon learn of Belerofon's safety and tolerability.
Continue reading »The results from the Phase I study with XTL-6865, a new compound being tested in patients with chronic Hepatitis C, are promising. In addition to the detailed outcome of this study, you'll learn how XTL-6865 may become a viable treatment option for patients with Hepatitis C undergoing liver transplantation, or for individuals with chronic Hepatitis C who have low viral loads.
Continue reading »A new drug called Infergen is opening new doors for people infected with the Hepatitis C virus who are not responding to standard treatment. Learn why this treatment option is recommended for non-responders, and other key information to share with your physician in determining whether Infergen may be right for you.
Continue reading »Roche will soon test a new treatment strategy in Hepatitis C patients who have a high viral load and are overweight. Individuals with hard-to-treat characteristics will be particularly interested in the result of this trial examining the effect of combining different levels of PEGASYS and ribavirin.
Continue reading »Preliminary results assessing Pharmasset's R7128 treatment for Hepatitis C genotype 1 are encouraging. This well-tolerated polymerase inhibitor will now be evaluated on an ascending dose schedule. Due to current therapies for genotype 1 having a low HCV eradication rate, R7128's development is worthy of attention.
Continue reading »Rockefeller University scientists researching the HIV virus recently discovered how a protein commonly found in the liver is necessary for Hepatitis C infection. By targeting this specific protein, scientists may develop more effective treatment strategies for Hepatitis C.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
